CAR-T Meeting 2024 | How will novel agents & CAR-T cells affect the future treatment landscape in B-ALL?
Alex Rampotas
• 15 Feb 2024
Alex Rampotas, MD, University College London, London, UK, briefly discusses advances that have been made in the treatment of B-cell acute lymphoblastic leukemia (B-ALL), highlighting the excitement around CAR-T cells and other immune therapies, including bispecific T-cell engagers (TCEs). Dr Rampotas hopes that these agents will move into the upfront setting and eventually improve outcomes for patients. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Conference fees: Gilead.
